Immunotherapy prevents dangerous blood transfusions in foetus
Nipocalimab offers a safe and effective alternative to traditional treatments
Paragraph 1
A new study has shown that the drug nipocalimab is a safe and effective alternative to traditional treatments for preventing a dangerous blood transfusion in foetuses. The study, published in the journal Blood, found that nipocalimab was able to prevent the need for a blood transfusion in 80% of cases, compared to just 50% of cases in the control group.
Paragraph 2
Nipocalimab is a humanised monoclonal antibody that targets the FcRn receptor, which is responsible for the transport of antibodies across the placenta. By blocking the FcRn receptor, nipocalimab prevents the transfer of maternal antibodies to the foetus, which can lead to haemolytic disease of the newborn (HDN).
Paragraph 3
HDN is a condition that occurs when the mother's immune system attacks the foetus's red blood cells. This can lead to anaemia, jaundice, and even death. Traditional treatments for HDN include blood transfusions and intrauterine blood transfusions (IUTs), which are both invasive procedures that can carry risks for the mother and the foetus.
Paragraph 4
Nipocalimab is a promising new treatment for HDN because it is non-invasive and does not carry the same risks as traditional treatments. The study findings suggest that nipocalimab could be a valuable addition to the armamentarium of treatments for HDN.
Comments